Sunshine Biopharma Reports 2023 First Quarter Results: Revenues Up 2,100%

May 11, 2023

https://www.globenewswire.com/news-release/2023/05/11/2666793/35334/en/Sunshine-Biopharma-Reports-2023-First-Quarter-Results-Revenues-Up-2-100.html

MONTREAL, May 11, 2023 (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2023 first quarter report. The Report shows gross revenues of $4,894,053 as of March 31, 2023, an increase of more than 2,100% over the same period in 2022. The increase was largely due to the prescription drugs sales of Nora Pharma Inc., a generic pharmaceuticals company that Sunshine Biopharma acquired in October 2022.

Read more at globenewswire.com

Related news for (SBFM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.